Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | S100B | P04271 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31398189 | 0.86 | CYP3A4 (0.43) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL27982658 | 0.83 | CYP3A4 (0.48) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL10798531 | 0.81 | CYP3A4 (0.46) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL1198813 | 0.79 | ALDH1A1 (0.44) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL29566675 | 0.79 | ALDH1A1 (0.44) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL2319989 | 0.79 | ALDH1A1 (0.39) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL10753626 | 0.77 | NCEH1 (0.42) | ALDH1A1TSHRPOLBNCEH1CYP1A2 | |
| SCHEMBL28457584 | 0.77 | CYP3A4 (0.38) | CYP3A4ALDH1A1TDP1TSHRPOLB | |
| SCHEMBL31152966 | 0.75 | CYP3A4 (0.36) | CYP3A4ALDH1A1TDP1TSHRPIK3CA | |
| SCHEMBL10989519 | 0.75 | ALDH1A1 (0.48) | CYP3A4ALDH1A1TDP1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-111683955-B | Compound and organic light-emitting element comprising same | 株式会社LG化学 | 2023-12-08 | — | — | CN | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116813610-A | Selenophene-containing cycloindole sulfonate inner salt and preparation method and application thereof | 德州学院 | 2023-09-29 | — | — | CN | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-6960640-B2 | Composition for optical material | MITSUBISHI GAS CHEMICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040147708-A1 | Composition for optical material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1426392-A1 | COMPOSITION FOR OPTICAL MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-1992019622-A1 | ARYLLITHIUM PROCESS | FMC CORPORATION (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5099044-A | ORGANOMETALLIC COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-03-24 | — | — | US | disclosed |
| EP-0399021-A1 | ORGANOALUMINIUM, ORGANOGALLIUM AND ORGANOINDIUM COMPOUNDS AND THEIR USE FOR THE GAS-PHASE DEPOSITION OF METAL ON SUBSTRATES | MERCK PATENT GmbH (DE) | 1990-11-28 | — | — | EP | disclosed |
| WO-1990006315-A1 | ORGANOALUMINIUM, ORGANOGALLIUM AND ORGANOINDIUM COMPOUNDS AND THEIR USE FOR THE GAS-PHASE DEPOSITION OF METAL ON SUBSTRATES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-06-14 | — | — | WO | disclosed |
| US-4847438-A | INSECTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-07-11 | — | — | US | disclosed |
| EP-0321010-A1 | New 11-arylsteroid compounds | AKZO N.V. (NL) | 1989-06-21 | — | — | EP | disclosed |
| US-4668701-A | Pesticides | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP3A4 4044/4885ALDH1A1 1816/4885TDP1 3446/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP3A4 4280/4885ALDH1A1 1957/4885TDP1 2880/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CYP3A4 3117/4885ALDH1A1 4127/4885TDP1 2579/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP3A4 2558/4885ALDH1A1 3580/4885TDP1 3669/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP3A4 3974/4885ALDH1A1 2681/4885TDP1 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.